Journal of Angiotherapy最新文献

{"title":"Precision Medicine in Lymphoid Malignancies","authors":"","doi":"10.25163/angiotherapy.635c","DOIUrl":"https://doi.org/10.25163/angiotherapy.635c","url":null,"abstract":"With the introduction of high-throughput sequencing technologies, the molecular landscape of major lymphoid malignancies was rapidly unraveled. While a few lymphoid neoplasms were characterized by a predominant gene mutation (e.g. Waldenström's macroglobulinemia and hairy cell leukemia), the majority demonstrated a highly diverse genomic landscape with a high number of recurrent mutations. These studies have not only furthered our understanding of the onset and evolution of lymphoid malignances, but also provided us with new biomarkers that can improve diagnostics, prognostication as well as guide clinical decision-making in lymphoid malignancies. In this lecture, I will highlight clinically relevant diagnostic, prognostic and predictive biomarkers that are used today in clinical diagnostics of chronic lymphocytic leukemia (CLL), one of the most frequent lymphoid malignancies, also as a basis for treatment decisions on novel targeted therapies. I will also highlight future directions in this rapidly evolving field.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"269 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116840123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Treatment Resistance in Head and Neck Cancer through Unravelling Molecular Mechanisms","authors":"Dr. Mitsumi Terada, Dr. Yolanda Augustin, Dr. Mastura, Siti Nursyahirah Bakar, Kue Chin Siang, Kaynat Khimani, Mohd Faiz, Abdul Ghani, Rozana Othman, Noraziah Nordin, M. H. Elias, Kamran Ashraf, Nur Fatin, Aina Nabila Basri, Wasim Ahmad, Mohammad Humayoon Amini, Pei San, Annie Wai, Yeeng Chai, S. Yee, Shiyin Ooi, Siew Kit Ng, S. Cheong, Dhayaalini Bala Gopal, Yin Quan Tang, Amir Imran, Faisal Hamdi, Jonathan Lim, Chee Woei, U. Daut, H. S. Hin, J. Stanslas, Jia-Wern Pan, P. Ng, Muhammad Mamduh, Ahmad Zabidi, Putri Nur Fatin, J. Teo, S. N. Hasan, Cheng Har Yip, P. Rajadurai, L. Looi, N. Aishah, Mohd Taib, O. Rueda, Carlos Caldas, S. Chin, J. Lim, S. Teo, Laith Marashdeh, T. Karuppiah, Bahariah Khalid, Salsabiilaa M. Razib, Nadiah Mad Nasir, Muhammad A M. Latif, Nur Qurratu, Ain A. Nordin, Pavithren Devakrishnan, U. Rahim, Marami Mustapa, Che Roos, Nursiati Taridi, Armania Nurdin, Yasmin Anum, Mohd Yusof, U. T. Ferdous, Saila Ismail, K. Shaari, Zetty Norhana, Balia Yusof, Yuan Seng Wu, Naaif Mohamed, Yoon-Ye","doi":"10.25163/angiotherapy.633c","DOIUrl":"https://doi.org/10.25163/angiotherapy.633c","url":null,"abstract":"Head and neck cancer is a common malignancy worldwide and carries a poor prognosis when it is diagnosed late. Treatment itself often carries significant morbidity and impairs quality of life. There have been few actionable targets for squamous cell carcinoma of the head and neck, notably anti-epidermal growth factor receptor monoclonal antibody cetuximab and antiPD1 immunotherapy that have reached clinical use. We studied a polymorphism in the extracellular semaphorin domain of C-MET in the context of SCC head/neck and lung, uncovering a novel mechanism conferring biological aggressiveness and potential for therapeutic intervention. TP53 mutations are the most common somatic mutations in SCCHN and we studied the gain of function mutation p53R158G in the S4 strand of the DNA binding domain, uncovering the mechanism of carcinogenicity. In South East Asia including Malaysia and Singapore, nasopharyngeal carcinoma is associated with EBV and is the commonest head and neck malignancy, with a propensity for recurrence and metastases. We have interest in development of anti-vascular endothelial growth factor therapy as a means to overcome treatment resistance, and some of this work will be described in this presentation.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128935619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploiting New Cancer Drug Targets that Drive Drug Resistant and Metastatic Disease","authors":"","doi":"10.25163/angiotherapy.6310c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6310c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114625612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ATLAS Project and the Future of International Collaborative Clinical Research in Asia","authors":"","doi":"10.25163/angiotherapy.636c","DOIUrl":"https://doi.org/10.25163/angiotherapy.636c","url":null,"abstract":"National Cancer Center Japan has initiated ATLAS (Asian Clinical Trials Network for Cancers) project since 2020 with financial support from AMED that is a Japanese public funding agency. The goals of ATLAS are to strengthen multilateral cooperation with ATLAS member institutions and improve the cancer clinical research capabilities; establish robust infrastructure for conducting oncology trials with high quality clinical data; deliver novel drugs and practice changing research results to cancer patients. To achieve this goal, construction of well-organized governance as a cooperative group such as EORTC, SWOG, or JCOG is urgently needed. We have just started to prepare the establishment of the ATLAS Board that is the guardian of ATLAS’s sustainability.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124646384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical Analysis and Evaluation of Antioxidant and Antibacterial Activities of Crude and Fractionated Flower Extracts of Clitoria ternatea","authors":"","doi":"10.25163/angiotherapy.6319c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6319c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117344917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Tropomyosin Receptor Kinase C Expressing Cancer Cells through Synthetic Ligand Conjugate and Cyclophosphamide for Immunotherapy","authors":"","doi":"10.25163/angiotherapy.6315c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6315c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"216 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121552443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates on Treatment of Gastroesophageal Cancers","authors":"","doi":"10.25163/angiotherapy.639c","DOIUrl":"https://doi.org/10.25163/angiotherapy.639c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"47 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132760615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymmetric Total Synthesis of (-)-Swainsonine from Inexpensive and Commercially Available Starting Material, Ascorbic Acid","authors":"","doi":"10.25163/angiotherapy.6320c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6320c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132048729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Immunotherapy in 2022 - End of the Beginning","authors":"","doi":"10.25163/angiotherapy.632c","DOIUrl":"https://doi.org/10.25163/angiotherapy.632c","url":null,"abstract":"In the past over 10 years, the renaissance of cancer immunotherapy and its impact on cancer lives saved has been unprecedented. The first immune checkpoint inhibitor (ICI) anti-CTLA4Ig was approved in 2011 and the first CAR T cell therapy approved in 2017. Since then, 6 more ICIs have been approved across many cancer indications. Tumour mutational burden and microsatellite instability form critical biomarkers for the use of ICIs. In 2022, we are seeing a rise in combination therapies involving ICI. In cell therapy, CAR T cell therapy has made early important inroads in blood cancers. In solid tumours, challenges exist in reaching optimal clinical efficacy. Still, we see glimmers of hope. T Cell Receptor and tumour infiltrating lymphocyte T cell therapy have shown some striking benefit in some patients refractory to further treatments with little further alternatives. Other exciting developments are in the therapeutic areas of T cell engager, antibody drug conjugates and therapeutic cancer vaccines. – where clinical benefits have been achieved. Central in the development of new immunotherapies and generally cancer treatment is a deeper dissection and understanding of the tumour microenvironment, to better elucidate mechanisms, biomarkers, resistance and new targets. Immunotherapy now forms a vital pillar of cancer therapy with a trend towards more combinations showing greater impact. Challenges remain for cost of treatment and manufacturing capabilities. With more supersurvivors and complete remissions with such treatment even in advanced disease, we will surely see a better tomorrow for cancer patients.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131300548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Identification of a Group of Self-Assembling, Trimetallic Cryptands with Multi-Kinase Inhibitor Activity Using a Phenotypic Approach to Drug Discovery","authors":"","doi":"10.25163/angiotherapy.634c","DOIUrl":"https://doi.org/10.25163/angiotherapy.634c","url":null,"abstract":"Despite significant advances in the development of targeted anti-cancer drugs, the much hoped for paradigm shift in cancer survival has been blunted by the emergence of new mechanisms of drug resistance. The development of drugs with multiple mechanisms of action is one approach that has been adopted to circumvent this problem and in this talk, the use of a phenotypic approach to drug discovery based on potency and selectivity in vitro has been used to identify compounds that have multiple mechanisms of action. This talk will specifically focus on the discovery, preclinical activity and mechanism of action of self-assembling trimetallic cryptands that have potent but selective activity against cancer cells in vitro and in vivo.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124309016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}